Buy PALI Ahead of ASCENTRA-UC Dosing Start - High-Risk, Asymmetric Biotech Play

Hook & thesis

Palisade Bio (Nasdaq: PALI) is a classic early-stage clinical play: a modest market cap, a clean balance sheet relative to company size, and a lead program - PALI-2108 - that is moving from Phase 1b into a global Phase 2b trial for ulcerative colitis. With Health Canada clearance for ASCENTRA-UC and multiple conference presentations in late September highlighting favorable safety, gut-targeted exposure, and a putative biomarker, the stock offers asymmetric upside versus downside for disciplined investors willing to accept binary clinical risk.

We are initiating a Buy on PALI with a mid-term trade plan. The combination of a cash runway that matters at this valuation (cash ~ $23.9M, enterprise value roughly $77M), a low current share price near the 52-week low, and technical oversold conditions creates a favorable entry point to own optionality on Phase 2b enrollment and early readouts that could re-rate the stock.

Business snapshot - what the market should care about

Palisade is a clinical-stage biopharmaceutical company focused on oral therapies for inflammatory bowel disease (IBD). Its lead program, PALI-2108, is an oral PDE4 inhibitor prodrug designed to achieve gut-targeted exposure - a profile that aims to deliver anti-inflammatory efficacy while limiting systemic PDE4-driven adverse events. That gut-targeted approach is the core fundamental driver: if PALI-2108 can show meaningful clinical activity in ulcerative colitis with good tolerability, it would be an attractive, differentiated oral option in a crowded IBD landscape where safety and oral convenience matter.

Recent developments and why they matter

• Health Canada cleared the Clinical Trial Application for ASCENTRA-UC on 09/23/2026. This expands the Phase 2b program’s geographic footprint alongside prior U.S. regulatory approval and enables more rapid enrollment.
• At UEG Week on 09/28/2026, Palisade presented four items on PALI-2108, including Phase 1b fibrostenotic Crohn’s disease data, early UC activity, favorable safety/tolerability, gut-targeted exposure, and a potential predictive biomarker. Those readouts de-risk the safety story and support moving into Phase 2.
• Management visibility at investor conferences in September aimed to increase awareness and provide additional Q&A windows for upcoming enrollment milestones.

Hard numbers - the facts you need

The simplest valuation framing: at a market cap near $194M and with roughly $24M in cash, the market is valuing Palisade’s enterprise (drugs in development, platform, liabilities) at about $77M. For a company that controls a differentiated oral PDE4 prodrug in Phase 2b, that is inexpensive if the trial shows any sign of efficacy or a clean safety profile. That said, early-stage clinical assets are binary and the current EV reflects that binary risk premium.

Technical and market positioning

Technically, PALI is near the 52-week low ($1.10) with an RSI of ~28 and short-interest that has been material (short interest ~31.7M as of 10/15 settlement, days to cover variable but meaningful). Moving averages show downtrend pressure (SMA50 around $1.63), which increases the chance of volatile moves in either direction. The low average price and elevated short interest mean upside can be swift on positive enrollment or safety updates, but downside can also cascade if the Phase 2 narrative stalls.

Catalysts - what could move the stock

• ASCENTRA-UC dosing start and early enrollment milestones - near-term catalyst as sites activate following Health Canada clearance (expected second half of 2026 for dosing).
• Interim safety or pharmacokinetic signals during early Phase 2 enrollment - continued confirmation of gut-targeting and tolerability would help re-rate the stock.
• Biomarker validation updates - presentation or poster data supporting a predictive biomarker could materially improve the probability of success and investor perception.
• Any partnership or licensing interest - a collaboration could be a re-rating event given lower current enterprise value.
• Primary efficacy readout expected in the second half of 2027 - longer-term but high-impact.

Trade plan - actionable and time-boxed

We are initiating a tactical long with the following rules:

• Entry: 1.10 (buy limit)
• Stop loss: 0.80 (hard stop)
• Target: 1.90 (take profits)
• Trade horizon: mid term (45 trading days) - plan to hold through initial site activations, early enrollment updates or a run of positive coverage and technical repair. We expect most near-term re-rating opportunities to occur as ASCENTRA-UC enrollment gets underway and early safety/pharmacokinetic confirmations are publicized within this window.

Why these levels? Entry at $1.10 sits right at the recent 52-week low and gives asymmetric upside if enrollment news or biomarker validation re-prices the asset. Target $1.90 is below the 52-week high and represents around 73% upside from entry - reasonable for a binary clinical swing trade while still respectful of the inherent risk. Stop $0.80 limits downside to approximately 27% from entry and protects capital in case the trial start slows, funding concerns emerge, or the broader biotech malaise continues.

Risk framework and counterarguments

PALI is not a low-risk stock. Below are the principal risks and a counterargument to our thesis:

• Clinical binary risk: Phase 2 programs can fail on efficacy or reveal tolerability issues not apparent in Phase 1b. A negative efficacy signal in ASCENTRA-UC would likely send shares materially lower.
• Funding risk: Free cash flow was negative (~-$18.19M) and cash on the balance sheet is finite (~$23.86M). If enrollment runs slowly or additional studies are required, Palisade may need to raise capital, which could be dilutive and pressure the share price.
• Technical & sentiment risk: The stock is technically weak versus moving averages, and short interest has been meaningful - downside could be exacerbated by negative momentum or broader sector weakness.
• Competition and commercial risk: IBD is a crowded space with established biologics and new small-molecule entrants. Even a positive Phase 2 signal must compete on efficacy, safety, and commercialization economics.
• Counterargument - the market may already be pricing in the most likely outcome: limited near-term progress and the need for further investment. If that is the case, upside could be muted even if ASCENTRA-UC proceeds as planned; positive early signals may be chased but absent a compelling efficacy readout later, the stock could return to current levels.

What would change my mind

I would scale back or flip to neutral/short if any of the following occur:

• Clear signs that ASCENTRA-UC enrollment is stalling or key sites are not activating in the expected timeframe.
• A near-term capital raise that appears dilutive and is priced well below current market expectations without a commensurate clinical catalyst.
• Clinical data that shows systemic exposure/toxicity inconsistent with the gut-targeted hypothesis.

Bottom line

Palisade is a high-risk, high-reward clinical-stage name. The combination of Health Canada clearance for ASCENTRA-UC, Phase 1b presentations supporting tolerability and gut-targeting, a modest enterprise value, and technical oversold conditions make it a reasonable candidate for a mid-term tactical long. Our trade plan is disciplined: enter at $1.10, stop at $0.80, target $1.90, and hold for roughly 45 trading days to capture site activation and early enrollment momentum. Investors should size positions conservatively and be prepared for binary volatility.

Key dates and upcoming monitoring checklist

• Monitor site activation and first patient dosing announcements (ongoing following 09/23/2026 clearance).
• Watch scientific meetings and company presentations for biomarker or PK/safety updates.
• Track trading volume, short-interest updates, and any financing announcements.

Trade idea: Buy at 1.10, Stop 0.80, Target 1.90. Hold mid term (45 trading days) and reassess on enrollment and safety signals.